Expert consensus for the treatment of disseminated intravascular coagulation in Japan

Thrombosis Research

Volumn 125, Issue 1, 2010, Pages 6-11

  Wada, Hideo ^a   Asakura, Hidesaku ^b   Okamoto, Kohji ^c   Iba, Toshiaki ^d   Uchiyama, Toshimasa ^e   Kawasugi, Kazuo ^f   Koga, Shin ^g   Mayumi, Toshihiko ^h   Koike, Kaoru ⁱ   Gando, Satoshi ^j   Kushimoto, Shigeki ^k   Seki, Yoshinobu ^l   Madoiwa, Seiji ^m   Maruyama, Ikuro ⁿ   Yoshioka, Akira ^o  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^d JUNTENDO UNIVERSITY   (Japan)

^e National Hospital Organization   (Japan)

^f TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g UNIVERSITY OF SHIZUOKA   (Japan)

^h NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁱ KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^j HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^k NIPPON MEDICAL SCHOOL   (Japan)

^l Niigata Prefectural Shibata Hospital   (Japan)

^m JICHI MEDICAL UNIVERSITY   (Japan)

ⁿ KAGOSHIMA UNIVERSITY   (Japan)

^o NARA MEDICAL UNIVERSITY   (Japan)

more..

Author keywords

DIC; guideline; recommendation; sepsis; treatment

Indexed keywords

ACTIVATED PROTEIN C; AMINOCAPROIC ACID; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ANTITHROMBIN; ARGATROBAN; DALTEPARIN; DANAPAROID; DROTRECOGIN; FIBRINOGEN; FRESH FROZEN PLASMA; GABEXATE MESILATE; HEPARIN; HEPARINOID; LOW MOLECULAR WEIGHT HEPARIN; NAFAMSTAT MESILATE; PROTEINASE INHIBITOR; RECOMBINANT THROMBOMODULIN; RETINOIC ACID; THROMBOCYTE CONCENTRATE; TISSUE FACTOR PATHWAY INHIBITOR; TRANEXAMIC ACID;

ACUTE HEART INFARCTION; ANTICOAGULANT THERAPY; BLEEDING; BLOOD CLOTTING TEST; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; DEEP VEIN THROMBOSIS; DIAGNOSTIC TEST; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; EVIDENCE BASED MEDICINE; FIBRINOGEN BLOOD LEVEL; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INFECTION; JAPAN; LOW DRUG DOSE; LUNG EMBOLISM; MEDICAL EXPERT; MEDICAL SOCIETY; PANCREATITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTHROMBIN TIME; REVIEW; SEPSIS; SURGICAL DRAINAGE; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOSIS; THROMBOSIS PREVENTION; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ANTICOAGULANTS; CONSENSUS; DISSEMINATED INTRAVASCULAR COAGULATION; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; JAPAN; SERINE PROTEINASE INHIBITORS; SOCIETIES, MEDICAL;

EID: 76449097783     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2009.08.017     Document Type: Review

References (51)

1. Müller-Berghaus G., ten Cate H., and Levi M. Disseminated intravascular coagulation: Clinical spectrum and established as well as new diagnostic approaches. Thromb Haemost 86 (2001) 1327-1330
2. Taylor Jr. F.B., Toh C.H., Hoots W.K., Wada H., and Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation - On behalf of the Scientific Subcommittee on disseminated intravascular coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Thromb Haemost 86 (2001) 1327-1330
3. Warren B.L., Eid A., Singer P., Pillay S.S., Carl P., Novak I., et al. High-dose antithrombin in severe sepsis. A randomized controlled trial. JAMA 286 (2001) 1869-1878 (Level 1b)
4. Bernard G.R., Vincent J.L., Laterre P.F., Larosa S.P., Dhainaut J.F., Lopez-Rodriguez A., et al. Efficacy and safety of recombinant human protein C for severe sepsis. N Engl J Med 8 (2001) 699-709 (Level 1b)
5. Abraham E., Reinhart K., Opal S., Demeyer I., Doig C., Rodriguez A.L., et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 290 (2003) 238-247 (Level 1b)
6. Dhainaut J.F., Yan S.B., Joyce D.E., Pettilä V., Basson B., Brandt J.T., et al. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost 2 (2004) 1924-1933
7. Levi M., Toh C.H., Thachil J., and Watson H.G. Guidelines for the diagnosis and management of disseminated intravascular coagulation. Br J Haematol 145 (2009) 24-33
8. Maruyama I., Sakata Y., Wada H., Asakura H., Okajima K., Gando S., et al. Japanese Society of Thrombosis Hemostasis/ DIC subcommittee: Expert consensus baced evidence for the treatment of disseminated intravascular coagulation due to infection. Jap J Thromb Hemost 20 (2009) 77-113
9. Levels of Evidence and Grades of Recommendations in Centre for evidence-Based Medicine (2001). http://www.cebm.net/levels_of_evidence.asp http://www.cebm.net/levels_of_evidence.asp
10. Kish M.A., and Infectious Diseases Society of America. Guide to development of practice guidelines. Clin Infect Dis 32 (2001) 851-854
11. Kobayashi N., Maekawa T., Takada M., Tanaka H., and Gonmori H. Criteria for diagnosis of DIC based on the analysis of clinical and laboratory findings in 345 DIC patients collected by the Research Committee on DIC in Japan. Bibl Haemotol 49 (1983) 265-275
12. Gando S., Iba T., Eguchi Y., Ohtomo Y., Okamoto K., Koseki K., et al. Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med 34 (2006) 625-631
13. Gando S., Wada H., Asakura H., Iba T., Eguchi Y., Okamoto K., et al. Evaluation of new Japanese diagnostic criteria for disseminated intravascular coagulation in critically ill patients. Clin Appl Thromb Hemost 11 (2005) 71-76
14. Wada H., Gabazza E.C., Asakura H., Koike K., Okamoto K., Maruyama I., et al. Comparison of diagnostic criteria for disseminated intravascular coagulation (DIC): diagnostic criteria of the International Society of Thrombosis and Haemostasis (ISTH) and of the Japanese Ministry of Health and Welfare for overt-DIC. Am J Hematol 74 (2003) 17-22
15. Dellinger R.P., and Vincent J.L. The Surviving Sepsis Campaign sepsis change bundles and clinical practice. Crit Care 9 (2005) 653-654
16. Tallman M.S., Andersen J.W., Schiffer C.A., Appelbaum F.R., Feusner J.H., Woods W.G., et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 100 (2002) 4298-4302 (Level 1b)
17. Aoki N., Matsuda T., Saito H., Takatsuki K., Okajima K., Takahashi H., et al. A comparative double blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. Int J Hematol 75 (2002) 540-547 (Level 2b)
18. Saito H., Maruyama I., Shimazaki S., Yamamoto Y., Aikawa N., Ohno R., et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 5 (2007) 31-41 (Level 2b)
19. Sakuragawa N., Hasegawa H., Maki M., Nakagawa M., and Nakashima M. Clinical evaluation of low-molecular-weight heparin (FR-860) on disseminated intravascular coagulation (DIC)-a multicenter co-operative double-blind trial in comparison with heparin. Thromb Res 72 (1993) 475-500 (Level 2b)
20. Arbuthnot C., and Wilde J.T. Haemostatic problems in acute promyelocytic leukaemia. Blood Rev 20 (2006) 289-297
21. Polderman K.H., and Girbes A.R.J. Drug intervention trials in sepsis: divergent results. Lancet 363 (2004) 1721-1723
22. Yasunaga K., Ogawa N., Mori K., Aoki N., Matsuda T., Nakagawa M., et al. Evaluation of clinical effect of danaparoid sodium (KB-101) on disseminated intravascular coagulation (DIC): double blind comparative study. Jpn Pharmacol Ther 23 (1995) 2815-2834 (Level 2b)
23. Harada N., Okajima K., Kohmura H., Uchiba M., and Tomita T. Danaparoid sodium reduces ischemia/reperfusion-induced liver injury in rats by attenuating inflammatory responses. Thromb Haemost 97 (2007) 81-87
24. Ohno H., Kosaki G., Kambayashi J., Imaoka S., and Hirata F. FOY: [ethyl P-(6guanidinohexanoyloxy) benzoate] methanesulfonate as a serine proteinase inhibitor. I. Inhibition of thrombin and factor Xa in vitro. Thromb Res 19 (1980) 579-588
25. Ohno H., Kambayashi J., Chang S.W., and Kosaki G. FOY [ethyl p-(6-guanidinohexanoxy) benzonate] methaneslfonate as a serine protease inhibitor. II. In vivo effect on coagulofibrinolytic system in comparison with heparin or aprotinin. Thromb Res 24 (1981) 452-455
26. Hitomi Y., Ikari N., and Fujii S. Inhibitory effect of a new synthetic protease inhibitor (FUT-175) on the coagulation system. Haemostasis 15 (1985) 164-168
27. Wada H., Wakita Y., Nakase T., Shimura M., Hiyoyama K., Nagaya S., et al. Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun. Thromb Haemost 74 (1995) 848-852
28. Nishiyama T., Matsukawa T., and Hanaoka K. Is protease inhibitor a choice for the treatment of pre-or mild disseminated intravascular coagulation?. Crit Care Med 28 (2000) 1419-1422 (Level 2b)
29. Hsu J.T., Chen H.M., Chiu D.F., Chen J.C., Huang C.J., Hwang T.L., et al. Efficacy of gabexate mesilate on disseminated intravascular coagulation as a complication of infection developing after abdominal surgery. J Formos Med Assoc 103 (2004) 678-684 (Level 2b)
30. Kosaki G., Kambayashi J., Hirabayashi A., Mori K., Uchida T., Abe T., et al. Evaluation of clinical effect of FOY on DIC: multi-center clinical comparative study. Igaku no Ayumi 124 (1983) 144-154 (Level 2b)
31. Shibata S., Takahashi H., Aoki N., Takahashi H., Aoki N., Matsuda T., et al. Evaluation of clinical effect of FUT-175 on DIC: multi-center clinical comparative study. Rinsho to Kenkyu 65 (1988) 921-940
32. Rosenberg R.D., and Damus P.S. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem 248 (1973) 6490-6505
33. Okabayashi K., Wada H., Ohta S., Shiku H., Nobori T., and Maruyama K. Hemostatic markers and the sepsis-related organ failure assessment score in patients with disseminated intravascular coagulation in an intensive care unit. Am J Hematol 76 (2004) 225-229
34. Mizutani A., Okajima K., Uchiba M., Isobe H., Harada N., Mizutani S., et al. Antithrombin reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation through promotion of prostacyclin production. Blood 101 (2003) 3029-3036
35. Vinazzer H. Therapeutic use of antithrombin III in shock and disseminated intravascular coagulation. Semin Thromb Hemost 15 (1989) 347-352 (Level 2b)
36. Dzinic L., Marenovic T., and Lakic-Trajkovic Z. Clinical study of the therapeutic value of Kybernin in the treatment of antithrombin III deficiency. Med Pregl 44 (1991) 245-248 (Level 2b)
37. Albert J., Blomqvist H., Gardlund B., Jakobsson J., Svensson J., and Blombäck M. Effect of antithrombin concentrate on haemostatic variables in critically ill patients. Acta Anaesthesiol Scand 36 (1992) 745-752 (Level 2b)
38. Fourrier F., Chopin C., Huart J.J., Runge I., Caron C., and Goudemand J. Double-blind, placebocontrolled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 104 (1993) 882-888 (Level 2b)
39. Waydhas C., Nast-Kolb D., Gippner-Steppert C., Trupka A., Pfundstein C., Schweiberer L., et al. High-dose antithrombin III treatment of severely injured patients : results of a prospective study. J Trauma 45 (1998) 931-940 (Level 2b)
40. Baudo F., Caimi T.M., de Cataldo F., Ravizza A., Arlati S., Casella G., et al. Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. Intensive Care Med 24 (1998) 336-342 (Level 2b)
41. Eisele B., Lamy M., Thijs L.G., Keinecke H.O., Schuster H.P., Matthias F.R., et al. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med 24 (1998) 663-672 (Level 2b)
42. Hoffmann J.N., Muhlbayer D., Jochum M., and Inthorn D. Effect of long-term and high-dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis. Crit Care Med 32 (2004) 1851-1859 (Level 2b)
43. Kienast J., Juers M., Wiedermann C.J., Hoffmann J.N., Ostermann H., Strauss R., et al. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 4 (2005) 90-97 (Level 2b)
44. Wiedermann C.J., and Kaneider N. A systematic review of antithrombin concentrate use in patients with disseminated intravascular coagulation of severe sepsis. Blood Coagulation and Fibrinolysis 17 (2006) 521-526 (Level 2a)
45. Mahendra P., Keeling D.M., Hood I.M., Baglin T.P., and Marcus R.E. Fatal thromboembolism in acute promyelocytic leukaemia treated with a combination of all-trans retinoic acid and aprotonin. Clin Lab Haematol 18 (1996) 51-52 (Level 4)
46. Pogliani E.M., Rossini F., Casaroli I., Maffe P., and Corneo G. Thrombotic complications in acute promyelocytic leukemia during all-trans-retinoic acid therapy. Acta Haematol 97 (1997) 228-230 (Level 4)
47. AABB. Blood Transfusion Therapy; A Physician's Handbook. 7th ed (2002) 27
48. Schiffer C.A., Anderson K.C., Bennett C.L., Bernstein S., Elting L.S., Goldsmith M., et al. Clinical Practice Guidelines of the American Society of Clinical Oncology. J Clin Oncol 19 (2001) 1519-1538
49. O'Shaughnessy D.F., Atterbury C., Bolton Maggs P., Murphy M., Thomas D., Yates S., et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 126 (2004) 11-28
50. Ono T., Mimuro J., Madoiwa S., Soejima K., Kashiwakura Y., Ishiwata A., et al. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood 107 (2006) 528-534
51. Wiedermann C.J., Hoffmann J.N., Juers M., Ostermann H., Kienast J., Briegel J., et al. High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Crit Care Med 34 (2006) 285-292 Level 1a